Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
Globe Newswire•02/11/2026•07:00 ET
0
Key Highlights
- ➤Ocular Therapeutix will report Q3 2026 financial results November 9, 2026
- ➤AXPAXLI is in Phase 3 trials for wet AMD and diabetic retinal disease
- ➤OTX-TIC completed Phase 2; Ocular is evaluating next steps
- ➤DEXTENZA is FDA-approved for post-surgical ocular inflammation and pain
BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.
Get started
Create a free account to read the full story.